CTOs on the Move

Antiva Biosciences

www.antivabio.com

 
Antiva Biosciences, Inc. is a clinical stage biopharmaceutical company developing novel, topical therapeutics for the treatment of diseases caused by HPV infection. The company was founded as Hera Therapeutics in 2012 by Dr. Karl Hostetler at The University of California San Diego and builds on his anti-viral expertise as co-founder of Triangle Pharmaceuticals and Chimerix. Antiva`s chemistry platform has yielded over two hundred proprietary pro-drug compounds that are designed to enhance the therapeutic index of known, potent antivirals.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.antivabio.com
  • 6000 Shoreline Court Suite 203
    South San Francisco, CA USA 94080
  • Phone: 650.822.1400

Executives

Name Title Contact Details

Funding

Antiva Biosciences raised $22M on 03/28/2017
Antiva Biosciences raised $60M on 07/10/2018
Antiva Biosciences raised $31M on 11/02/2021

Similar Companies

Indi Molecular

Indi Molecular provides PCCs for research and development in the fields for imaging agents for medical diagnostic imaging. Indi Imaging medical diagnostic research is provided to corporate partners, both as sponsored research or in partnership. Research and development using novel and custom PCCs, including PCCs that are membrane permeable, are provided for under the PCC Inside brand for uses that include antigen detection for both cell and tissue analysis, therapeutics or in vitro diagnostics.

Syantra

With a cancer diagnosis, early detection means better outcomes. It means hope. But when it comes to breast cancer, more than half of women have a reduced opportunity for an early, life-saving diagnosis. That`s why we`re developing Syantra DX: a blood test to detect breast cancer. It`s a revolutionary, rapid, economical approach to breast cancer screening that`s accurate regardless of the test recipient`s family history, age or tissue density.

Carmell Therapeutics

Our groundbreaking plasma-based materials are designed to improve patient outcomes and reduce healthcare costs across a variety of surgical procedures.

Tonix Pharmaceuticals

Tonix Pharmaceuticals develops first-in-class medicines for common disorders of the central nervous system, including fibromyalgia, post-traumatic stress disorder, and episodic tension-type headache. These disorders are characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and significant economic burden. Tonix`s lead product candidate, TNX-102 SLAttribution (cyclobenzaprine HCl sublingual tablet), is designed to be a fundamental advance in sleep hygiene and pain management for patients suffering from fibromyalgia and post-traumatic stress disorder (PTSD). Product candidate TNX-201Attribution ((R)-isometheptene mucate) is in development for episodic tension-type headache, the most common form of headache.

Transcept Pharmaceuticals, Inc.

Transcept Pharmaceuticals, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.